Bilimsel çalışmalar

Doç. Dr. Yasin Kutlu

56 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study

    Research Square, 2026

    DOI 10.21203/rs.3.rs-11204389/v1 Açık erişimli tam metinKaynak: OpenAlex

  2. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Açık erişimli tam metinKaynak: OpenAlex

  3. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    Pharmaceuticals, 2026

    DOI 10.3390/ph19040587 PMID 42075843 Açık erişimli tam metinKaynak: OpenAlex

  4. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083118 PMID 42074920 Açık erişimli tam metinKaynak: OpenAlex

  5. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000610 PMID 42267536 Kaynak: OpenAlex

  6. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Kaynak: OpenAlex

  7. Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3–6 Month Relapse Window

    Current Oncology, 2026

    DOI 10.3390/curroncol33080472 PMID 42645377 Açık erişimli tam metinKaynak: OpenAlex

  8. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Açık erişimli tam metinKaynak: OpenAlex

  9. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s647399 PMID 42936308 Açık erişimli tam metinKaynak: OpenAlex

  10. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-09707-3 PMID 40653542 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  11. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61030490 PMID 40142301 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  12. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2358458 PMID 38803194 Kaynak: OpenAlex

  13. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

    Cancers, 2024

    DOI 10.3390/cancers16122251 PMID 38927957 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  14. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

    International Journal of Clinical Oncology, 2024

    DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 atıf (Europe PMC) Kaynak: OpenAlex

  15. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

    Current Problems in Cancer, 2024

    DOI 10.1016/j.currproblcancer.2024.101102 PMID 38735211 2 atıf (Europe PMC) Kaynak: OpenAlex

  16. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study

    Expert Opinion on Pharmacotherapy, 2024

    DOI 10.1080/14656566.2024.2337261 PMID 38568074 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  17. 71P The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: A Turkish Oncology Group (TOG) study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.102300 Açık erişimli tam metinKaynak: OpenAlex

  18. Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Neoadjuvan Tedavilerin Etkinliği: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2024

    DOI 10.32708/uutfd.1515582 Açık erişimli tam metinKaynak: OpenAlex

  19. Is Clinical Risk Score a Useful Predictive Marker of Early Recurrence Among Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors?

    Eurasian Journal of Medical Investigation, 2024

    DOI 10.14744/ejmi.2024.52208 Kaynak: YÖK Akademik

  20. Multicenter Real-World Experience from the Turkish Oncology Group: Sotorasib in KRAS G12C-Mutated NSCLC

    Eurasian Journal of Medical Investigation, 2024

    DOI 10.14744/ejmi.2024.40471 Kaynak: YÖK Akademik

  21. Real-World Outcomes Of Lu-177 PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Experience

    Research Square, 2023

    DOI 10.21203/rs.3.rs-3365105/v1 Açık erişimli tam metinKaynak: OpenAlex

  22. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

    Medicine, 2023

    DOI 10.1097/md.0000000000033432 PMID 37058061 14 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  23. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Chemotherapy and Pharmacology, 2023

    DOI 10.1007/s00280-023-04592-x PMID 37773537 8 atıf (Europe PMC) Kaynak: OpenAlex

  24. Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

    International Immunopharmacology, 2023

    DOI 10.1016/j.intimp.2023.110947 PMID 37742369 5 atıf (Europe PMC) Kaynak: OpenAlex

  25. Integrated FDG-PET/CT contribution over cross-sectional imaging in recurrence or progression of pancreaticobiliary neoplasms

    Abdominal Radiology, 2023

    DOI 10.1007/s00261-023-04109-3 PMID 37991533 1 atıf (Europe PMC) Kaynak: OpenAlex

  26. SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

    Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 2023

    DOI 10.26650/iuitfd.1211556 Açık erişimli tam metinKaynak: OpenAlex

  27. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data

    Journal of Gastrointestinal Cancer, 2023

    DOI 10.1007/s12029-023-00953-0 PMID 37347353 1 atıf (Europe PMC) Kaynak: OpenAlex

  28. The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.00187 Açık erişimli tam metinKaynak: OpenAlex

  29. Erken Evre Triple Negatif Meme Kanserinde Sağkalım Sonuçları ve Prognostik Faktörler: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2023

    DOI 10.32708/uutfd.1356458 Açık erişimli tam metinKaynak: OpenAlex

  30. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  31. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04087-x PMID 35689097 11 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  32. Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock

    Journal of Experimental and Clinical Medicine, 2022

    DOI 10.52142/omujecm.39.1.1 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  33. Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients With Extensive-Stage Small Cell Lung Carcinoma Treated with Atezolizumab in Combination with Chemotherapy: Single Center Experience

    Social Science Research Network, 2022

    DOI 10.2139/ssrn.3977779 1 atıf (Semantic Scholar) Açık erişimli tam metinKaynak: ORCID

  34. THE RELATIONSHIP BETWEEN sTREM-1 AND ACTIVATION OF INFLAMMATORY BOWEL DISEASES

    Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 2021

    DOI 10.26650/iuitfd.2020.0090 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  35. P40.20 Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.08.457 Açık erişimli tam metinKaynak: OpenAlex

  36. Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer

    Acta Oncologica Turcica, 2021

    DOI 10.5505/aot.2021.26576 Açık erişimli tam metinKaynak: OpenAlex

  37. The relationship between insulin resistance, obesity, and endotrophin

    International Journal of Diabetes in Developing Countries, 2020

    DOI 10.1007/s13410-019-00780-9 5 atıf (OpenAlex) Kaynak: OpenAlex

  38. Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease

    Medical Principles and Practice, 2019

    DOI 10.1159/000500106 PMID 30995640 34 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  39. Serum endotrophin levels in patients with heart failure with reduced and mid-range ejection fraction

    European Journal of Internal Medicine, 2019

    DOI 10.1016/j.ejim.2019.04.016 PMID 31036437 8 atıf (Europe PMC) Kaynak: OpenAlex

  40. Reply to the Letter to the Editor “Adropin: Connection between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease”

    Medical Principles and Practice, 2019

    DOI 10.1159/000502106 PMID 31505512 Açık erişimli tam metinKaynak: OpenAlex

  41. Serum endotrophin levels in heart failure patients with reduced ejection fraction; a preliminary study

    2019

    Kaynak: OpenAlex

  42. Adult vaccination awareness in physicians

    BOĞAZİÇİ TIP DERGİSİ, 2019

    DOI 10.14744/bmj.2019.25733 Kaynak: YÖK Akademik

  43. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients

    International Urology and Nephrology, 2017

    DOI 10.1007/s11255-017-1556-4 PMID 28255639 12 atıf (Europe PMC) Kaynak: OpenAlex

  44. The effect of blood glucose regulation on iron metabolism and hepcidin in uncontrolled type 2 diabetic patients

    International Journal of Clinical and Experimental Medicine, 2016

    Kaynak: Scopus

  45. PP-037 PRIMARY BREAST LYMPHOMA

    Leukemia Research, 2014

    DOI 10.1016/s0145-2126(14)70091-8 Kaynak: OpenAlex

  46. 7.6. Ulusal bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler

    Kaynak: medipol.com.tr profil sayfası

  47. 7.1. Uluslararası hakemli dergilerde yayınlanan makaleler (SCI & SSCI & Arts and Humanities)

    Kaynak: medipol.com.tr profil sayfası

  48. 7.2. Uluslararası diğer hakemli dergilerde yayınlanan makaleler

    Kaynak: medipol.com.tr profil sayfası

  49. 7.3. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler

    Kaynak: medipol.com.tr profil sayfası

  50. 7.4. Yazılan uluslararası kitaplar veya kitaplarda bölümler

    Kaynak: medipol.com.tr profil sayfası